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ABSTRACT Peptidylarginine deiminase (PAD) enzymes convert histone arginine res-
idues into citrulline to modulate chromatin organization and gene expression.
Although PADs are expressed in anterior pituitary gland cells, their functional
role and expression in pituitary adenomas are unknown. To begin to address
these issues, we ﬁrst examined normal human pituitaries and pituitary adenomas
and found that PAD2, PAD4, and citrullinated histones are highest in prolactino-
mas and somatoprolactinomas. In the somatoprolactinoma-derived GH3 cell line,
PADs citrullinate histone H3, which is attenuated by a pan-PAD inhibitor. RNA
sequencing and chromatin immunoprecipitation (ChIP) studies show that the ex-
pression of microRNAs (miRNAs) let-7c-2, 23b, and 29c is suppressed by histone
citrullination. Our studies demonstrate that these miRNAs directly target the
mRNA of the oncogenes encoding HMGA, insulin-like growth factor 1 (IGF-1),
and N-MYC, which are highly implicated in human prolactinoma/somatoprolacti-
noma pathogenesis. Our results are the ﬁrst to deﬁne a direct role for PAD-
catalyzed histone citrullination in miRNA expression, which may underlie the eti-
ology of prolactinoma and somatoprolactinoma tumors through regulation of
oncogene expression.
KEYWORDS citrullination, epigenetics, prolactinoma, miRNA, oncogenes
Many proteins are regulated by posttranslational modiﬁcations (PTMs) which altertheir structure and function. One such modiﬁcation is citrullination, or deimina-
tion, in which the basic amino acid arginine is converted to the neutral, noncoded
residue citrulline (1). This modiﬁcation is catalyzed by the peptidylarginine deiminase
(PAD) family of enzymes composed of PAD1 to -4 and PAD6, although the last isoform
lacks catalytic activity (2). In addition to cytosolic targets, PAD2 and PAD4 citrullinate
nuclear proteins, such as histone tail arginine residues (3–5). Similar to acetylation and
methylation, histone citrullination either activates or represses gene expression, thus
contributing to the increasingly complex histone code (4, 6, 7). PADs are expressed in
brain, skin, muscle, female reproductive tissues, and anterior pituitary gland lactotrope
cells, suggesting a functional role for the enzymes in vivo (8–10).
The anterior pituitary gland contains ﬁve endocrine cell types, including lactotropes,
which secrete prolactin (PRL), and somatotropes, which secrete growth hormone (GH).
Somatolactotropes, a less understood, minor cell type, secrete both PRL and GH (11,
12). In humans and rodents, anterior pituitary cell populations can undergo dynamic
changes in plasticity during different physiological states (13). Such transformations are
critical for lactotrope cells, which dramatically increase in size, number, and connec-
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tivity during late pregnancy to increase PRL production for the initiation of lactation
(13–16). Yet uncontrolled proliferation can result in lactotrope-derived PRL-secreting
prolactinomas, which account for 40 to 60% of all diagnosed functional pituitary
adenomas (PAs) (17). Approximately 10 to 15% of PAs secrete GH, and the large
majority of these are somatoprolactinomas, which secrete both GH and PRL (17, 18). A
growing body of research implicates the overexpression of PADs in the pathogenesis of
multiple cancers and in tumor progression (5, 19, 20). Currently, it is unknown if
PAD-catalyzed histone citrullination alters gene expression in lactotrope cells or if it
contributes to prolactinoma/somatoprolactinoma pathogenesis (21).
Genomic studies of human prolactinomas and somatoprolactinomas show that
microRNA (miRNA) proﬁles differ between PA subtypes (22, 23). miRNAs are conserved
19- to 25-nucleotide (nt) noncoding RNAs that bind to complementary sequences
within target mRNAs to regulate their expression (22, 24). miRNA biogenesis begins
with transcription of a 200-nt primary miRNA (pri-miRNA) with a single miRNA or a
cluster of miRNAs embedded within its stem-loop structure(s) (22). The microprocessor
complex, a heterodimer of the RNase III enzyme Drosha and the double-stranded RNA
binding protein DiGeorge syndrome chromosomal region 8 (DGCR8), excises the
stem-loop, yielding a 60- to 100-nt precursor miRNA (pre-miRNA) (22, 25). Exportin-5
shuttles the pre-miRNA from nucleus to the cytoplasm, where the RNase III enzyme
Dicer removes the terminal loop to generate the 19- to 25-nt duplex miRNA interme-
diate. The duplex is loaded into the RNA-induced silencing complex (RISC), which
retains one strand and guides the mature miRNA to its binding site, commonly in a
target mRNA’s 3= untranslated region (UTR). miRNA binding inhibits translation and/or
promotes degradation of the mRNA transcript (22, 24, 25). Although miRNA expression
is epigenetically regulated by methylation and acetylation, it is unknown if histone
citrullination may likewise regulate miRNAs (25).
Bioinformatic analyses predict that more than 60% of human protein-coding genes
contain one or more conserved miRNA binding sites in their 3= UTRs, indicating that a
majority of such genes are susceptible to miRNA regulation (26). Some miRNAs, known
as tumor suppressor miRNAs, target the mRNA of oncogenes. For example, members of
the LET-7 family of miRNAs target Ras, Myc, and importantly, high-mobility-group
AT-hook 1 and 2 (HMGA1 and HMGA2) mRNAs, which are implicated in prolactinoma
and somatoprolactinoma pathogenesis (24, 27, 28). Therefore, it is not surprising that
global miRNA suppression promotes cancer cell transformation and is associated with
an increasing number of human neoplasias, including breast, lung, and thyroid cancers
and both prolactinomas and somatoprolactinomas (23, 24, 29, 30).
Here we report that human prolactinomas and somatoprolactinomas express high levels of
PAD2 and PAD4 and contain citrullinated histones. The rat somatoprolactinoma-derived GH3
cell line likewise expresses PAD2 and -4, which citrullinate histones to suppress the
expression of the tumor suppressor miRNAs let-7c-2, 23b (miR-23b), and miR-29c. When
histone citrullination is attenuated by the PAD inhibitor biphenyl-benzimidazole-Cl-
amidine (BB-ClA) or when PAD2 is knocked down, the miRNAs are reexpressed and
processed and subsequently target oncogene mRNAs. Speciﬁcally, these miRNAs target
HMGA1, insulin-like growth factor 1 (IGF-1), and N-MYC. GH3 proliferation is signiﬁ-
cantly decreased following PAD inhibition compared to vehicle-treated controls. Our
work is the ﬁrst to show that histone citrullination directly represses the expression of
tumor suppressor miRNAs, thus linking PADs to the overexpression of oncogenes in
pituitary adenomas.
RESULTS
Human prolactinomas and somatoprolactinomas express elevated levels of
PADs and citrullinated histones. PADs are expressed in the anterior pituitary gland,
but whether levels of these enzymes change in PAs is currently unknown. Thus, we ﬁrst
examined if PAD2 and -4 are expressed in normal human pituitaries as well as human
prolactinomas and somatoprolactinomas using immunohistochemistry (IHC). Normal
tissue sections (n  8 females and n  6 males) were probed with anti-PAD2 or
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anti-PAD4 antibodies, while pituitary tumor sections (n  11 prolactinoma and n  6
somatoprolactinoma) were also probed with an anti-H3Cit2,8,17 antibody. Represen-
tative normal human female and male pituitary sections show little PAD2 (Fig. 1Ai and
ii) or PAD4 (Fig. 1Aiii and iv) staining. Relative to the normal pituitary sections, an
exemplar prolactinoma displays low PAD2 (Fig. 1Bi) and moderate PAD4 (Fig. 1Biii)
staining; the somatoprolactinoma, however, has strong PAD2 (Fig. 1Bii) and PAD4 (Fig.
1Biv) expression. Consistent with elevated expression, PAD2 (Fig. 1Bi and ii) and PAD4
(Fig. 1Biii and iv) are localized to the nucleus and citrullinate histone H3 arginine
residues 2, 8, and 17 (H3Cit2,8,17 [Fig. 1Bv and vi]). These ﬁndings illustrate that PADs
and citrullinated histones are present in human prolactinomas and somatoprolactino-
mas at higher levels than in normal pituitaries.
PAD2 and PAD4 localize to the nucleus and citrullinate histones in the
somatolactotrope-derived GH3 cell line. To address PAD function, we used the GH3
cell line derived from a female rat somatoprolactinoma (31). Consistent with somato-
lactotrope data from Fig. 1, GH3 lysates also express PAD2 and PAD4 (Fig. 2A).
Cross-reactivity of the human PAD4 antibody with the rat isoform was assessed by
preabsorbing with a rat N-terminal PAD4 15-amino-acid peptide, which signiﬁcantly
attenuates signal. To determine subcellular localization, GH3 cells were ﬁxed and
stained with anti-PAD2 or anti-PAD4 antibodies and IgG as a negative control following
a standard immunocytochemistry (ICC) protocol. Confocal imaging conﬁrmed the
localization of both PAD isoforms in the cytoplasm and nuclei (Fig. 2B, arrows). The
nuclear localization of PAD2 and PAD4 suggests that the enzymes may citrullinate
histones in GH3 cells.
PAD4 
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H3cit2,8,17 
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20 μm 
Somatoprolacnoma 
100 μm 100 μm 
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FIG 1 Human prolactinomas and somatoprolactinomas express elevated levels of PADs and citrullinated histones. (A) Normal human pituitary
sections (n  8 female and n  6 male) were examined by IHC by probing with anti-PAD2 and anti-PAD4 antibodies or with an equal mass of
rabbit IgG as a negative control. Representative images for a 29-year-old female and 33-year-old male were taken with a Zeiss Axio Vert.A1
microscope using the 20 objective except for IgG, which was taken with a 10 objective. (B) Human prolactinoma (n  11) and somatopro-
lactinoma (n  6) sections were examined by IHC using anti-PAD2, anti-PAD4, and anti-H3Cit2,8,17 antibodies. Sections were probed with an
equal mass of rabbit IgG as a negative control. Representative images were taken using the 40 objective except for IgG, which was taken with
a 10 objective. The scale bars represent 100 m for the 10 objective, 50 m for the 20 objective, and 20 m for the 40 objective.
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To test this directly and conﬁrm our results in Fig. 1B that show citrullinated histones
in prolactinomas and somatoprolactinomas, GH3 cells were treated with either di-
methyl sulfoxide (DMSO) or 1.25 M BB-ClA every 3 h for a total of 14 h. Equal
concentrations of puriﬁed histones were examined by Western blotting with in vitro-
citrullinated histones as a positive control. Membranes were probed with an anti-
H3Cit2,8,17 antibody or anti-histone H3 as a loading control. Our results indicate that
GH3 cell histones are citrullinated under basal conditions, but PAD inhibition with
BB-ClA treatment caused a signiﬁcant 50% decrease in histone H3 citrullination (n 
3; P 0.01) (Fig. 3A and B). Thus, PADs catalyze the H3Cit2,8,17 epigenetic modiﬁcation
in GH3 cells, which is signiﬁcantly inhibited by BB-ClA.
The pan-PAD inhibitor BB-ClA decreases basal histone citrullination to regulate
the expression of pri-miRNAs in GH3 cells. Given that PADs citrullinate somatolac-
totrope histones, at issue is the identity of the genes epigenetically regulated by
citrullination. To address this, we performed RNA sequencing (RNA-seq) on GH3 cells
treated with either DMSO or 1.25 M BB-ClA following the experimental paradigm
described above. Total RNA from three independent experiments was collected and
submitted for sequencing. Bioinformatic analysis found that inhibition of PAD-catalyzed
citrullination signiﬁcantly upregulated 81 genes and downregulates 74 genes. The top
12 upregulated genes are listed in Fig. 3C. Interestingly, PAD inhibition induced
signiﬁcant expression of multiple pri-miRNAs. Thus, it appears that PAD-catalyzed
citrullination normally suppresses pri-miRNA expression. To the best of our knowledge,
this is the ﬁrst study showing that PAD-catalyzed citrullination directly regulates
pri-miRNA expression.
Inhibiting histone citrullination or knocking down PAD2 increases the expres-
sion of primary microRNAs let-7c, 23b, and 29c. miRNAs are implicated in the
A
PAD2 PAD4 
Merged 
B 
DAPI 
only 
IgG 
43 kDa 
72 kDa 
GH3 +Control 
PAD2 
β-acn 
PAD4 
β-acn 
Rat pepde pre-absorbed 
GH3 +Control GH3 
43 kDa 
72 kDa 
+Control 
FIG 2 PAD2 and PAD4 localize to the nucleus and citrullinate histones in the somatolactotrope-derived GH3 cell line. (A)
GH3 cells were lysed and subjected to Western blotting using anti-PAD2 and anti-PAD4 antibodies or an anti-PAD4
antibody that was preabsorbed with the N-terminal 15 amino acids of the rat PAD4 isoform. Anti--actin was used as a
loading control. To generate positive controls, GH3 cells were transiently transfected with a PAD2 or PAD4 expression
plasmid for 24 h and subsequently lysed. (B) GH3 cells were ﬁxed and examined by ICC using anti-PAD2 or anti-PAD4
antibodies or an equal mass of rabbit IgG as a negative control and stained with 4=,6-diamidino-2-phenylindole (DAPI;
blue). Arrows indicate nuclear PAD staining. Images were taken with a Zeiss LSM 710 confocal microscope using a 40
objective. The scale bars represent 10 m.
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etiology of prolactinomas and somatoprolactinomas (23, 29). Taken together with the
data in Fig. 3, this suggests that PADs may be an unexplored mechanism through which
pri-miRNA/miRNA expression promotes PAs. To conﬁrm our RNA-seq results, we vali-
dated the expression of pri-let-7c-2, pri-miR-23b, and pri-miR-29c in GH3s since their
respective mature miRNAs are associated with PAs and/or other human tumors (32–34).
Following the same experimental paradigm, independent sets of RNA were isolated
from GH3 cells and analyzed by qPCR using primers for pri-let-7c-2, pri-miR-23b, and
pri-miR-29c. The primers detect only pri-miRNA transcripts since the forward primers
are speciﬁc to regions that are removed during biogenesis. Our quantitative PCR (qPCR)
results conﬁrm a 2.5- to 4-fold increase in expression of each pri-miRNA transcript
following PAD inhibition with BB-ClA (n 4; P 0.001) (Fig. 4A). We next examined the
in vivo relevance of this ﬁnding using mouse pituitary primary cell cultures. Pituitaries
from wild-type mice were explanted, dispersed, and plated in complete medium
overnight. The following day, the cells were treated every 3 h for 14 total hours with
DMSO or BB-ClA and pri-miRNA levels examined by qPCR. As with GH3 cells, pri-let-7c-2,
pri-miR-23b, and pri-miR-29c expression was signiﬁcantly increased upon PAD inhibi-
tion (n 4; P 0.05 and P 0.01) (Fig. 4B). To conﬁrm the results in Fig. 4A by another
means, we next knocked down PAD2 and PAD4 in GH3 cells using small interfering
RNAs (siRNAs). GH3 cells were transiently transfected with rat PAD2, PAD4, and nontar-
geting siRNAs for 48 h. Knockdown signiﬁcantly decreased PAD2 and PAD4 expression
compared to nontargeting controls (n 5; P 0.05 and P 0.01) (Fig. 4C). siRNA-mediated
knockdown of PAD2 but not PAD4 resulted in a signiﬁcant increase in the expression of
pri-let7c2, pri-miR-23b, and pri-miR-29c (n  4; P  0.05) (Fig. 4D to F).
Given the signiﬁcant regulation that occurs at each step of miRNA biogenesis, we
next quantiﬁed mature miRNA following PAD inhibition in GH3 cells. Our results
indicate that mature miRNAs are also signiﬁcantly increased with BB-ClA treatment
compared to controls (n  4; P  0.05 and P  0.01) (Fig. 4G) (25, 34). Finally, we used
chromatin immunoprecipitation (ChIP) analysis to test if the changes in pri-miRNA
expression are associated with histone citrullination of the miRNA genes. Following
DMSO or BB-ClA treatment, GH3 cell lysates were incubated with the anti-H3Cit2,8,17
antibody and immunoprecipitated chromatin was analyzed by qPCR using primers
speciﬁc to each pri-miRNA gene. The results indicate that signiﬁcantly less of each
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FIG 3 The pan-PAD inhibitor BB-ClA decreases basal histone citrullination to regulate the expression of pri-miRNAs in GH3 cells. (A)
GH3 cells were treated with either DMSO or 1.25 M BB-ClA. Following cell lysis, histones were puriﬁed and examined by Western
blotting using anti-H3Cit2,8,17 antibody and anti-histone H3 antibody as a loading control. In vitro-citrullinated histones were used
as a positive control. (B) Western blots were quantiﬁed with Bio-Rad Image Lab; means were separated via a two-tailed t test (n 
3; P  0.01), and values are expressed as means  SEM. (C) GH3 cells were treated with either DMSO or 1.25 M BB-ClA. The RNA
from three independent experiments was puriﬁed and sequenced on an Illumina platform. Bioinformatic analysis identiﬁed 81
upregulated genes, of which the top 12 genes in DMSO- versus BB-ClA-treated GH3 cells are listed. Genes with Padj values of 0.05
were considered signiﬁcant.
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pri-miRNA gene is associated with citrullinated histones following PAD inhibition
compared to vehicle-treated control cells (n  3; P  0.05) (Fig. 5). Thus, blocking PAD
activity decreases H3Cit2,8,17 at the let-7c-2, miR-23b, and miR-29c genes. These data
show that histone citrullination is repressive and directly suppresses the expression of
these pri-miRNA genes.
PAD inhibition signiﬁcantly decreases oncogene mRNA and protein expression
in GH3 cells. HMGA1 and HMGA2 are nonhistone chromatin binding proteins that are
directly implicated in the pathogenesis of prolactinomas and somatoprolactinomas (28,
35, 36). IGF-1 and N-MYC are similarly associated with oncogenic processes (37–40).
TargetScan and visual analyses showed that the HMGA1, HMGA2, IGF-1, and N-MYC
mRNAs contain putative binding sites for let-7 family members, miR-23b, and/or
miR-29c (27, 32, 33). Given that histone citrullination suppresses pri-miRNA transcrip-
tion, we hypothesized that inhibiting PADs in GH3 cells would decrease HMGA1, IGF-1,
and N-MYC mRNAs due to the reexpression of miRNAs that promote transcript degra-
dation. To test this, we examined HMGA1, IGF-1, and N-MYC mRNA levels after 0, 12, 24,
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FIG 4 Inhibiting histone citrullination or knocking down PAD2 increases the expression of primary microRNAs let-7c, miR-23b, and miR-29c. (A)
GH3 cells were treated with either DMSO or 1.25 M BB-ClA and then lysed, and RNA was subjected to qPCR with primers speciﬁc to pri-let-7c-2,
pri-miR-23b, and pri-miR-29c. Results were quantiﬁed (n  4) and means were separated with a two-tailed t test. (B) Dispersed mouse pituitary
cells were treated with either DMSO or 1.25 M BB-ClA. Cells were lysed and puriﬁed RNA was subjected to qPCR with mouse primers for the
indicated pri-miRNAs. Experiments were quantiﬁed (n  4) and means were separated with a one-tailed paired t test. (C to F) GH3 cells were
transiently transfected with nontargeting, PAD2, and PAD4 siRNA constructs for 48 h. Following lysis and RNA puriﬁcation, samples were
examined by qPCR for expression of PAD2 and -4 (C), pri-let7c-2 (D), pri-miR-23b (E), and pri-miR-29c (F), with GAPDH as the endogenous
reference control. Means were separated with either a one-tailed paired t test (C; n  5) or a one-way repeated-measures analysis of variance
(ANOVA) with a post hoc Dunnett’s t test (D to F; n  4). (G) After DMSO or BB-ClA treatment, GH3 cells were lysed and puriﬁed small RNAs were
subjected to qPCR with TaqMan probes speciﬁc for let-7c, miR-23b, and miR-29c. U6 snRNA was used as an endogenous reference control.
Experiments were quantiﬁed and means were separated with a two-tailed t test (n  4). All values provided are means  SEM.
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and 48 h of treatment with 1.25 M BB-ClA or DMSO with inhibitor replenishment every
12 h. HMGA2 was not analyzed due to lack of expression in GH3 cells (27). Our results
indicate that HMGA1 and N-MYC mRNAs were signiﬁcantly downregulated following 24
and 48 h of PAD inhibition, while IGF-1 mRNA was signiﬁcantly decreased following 12,
24, and 48 h of BB-ClA (Fig. 6A to C) (n  3; P  0.05 and P  0.01). HMGA1, N-MYC,
and IGF-1 were also decreased following 48 h of BB-ClA treatment compared to
DMSO-treated controls (Fig. 6D to F). Importantly, after 48 h of BB-ClA treatment
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FIG 5 Citrullinated histones are directly associated with and repress primary miRNA expression in GH3 cells. For ChIP, GH3
protein-DNA complexes were immunoprecipitated with anti-H3Cit2,8,17, anti-histone H3 (positive control), or nonspeciﬁc IgG
(negative control). Cross-links were reversed, and the DNA was puriﬁed and subjected to qPCR analysis with pri-miRNA speciﬁc
primers. Means were separated with a one-tailed paired t test (n  3). All values provided are means  SEM.
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FIG 6 PAD inhibition signiﬁcantly decreases oncogene mRNA and protein expression in GH3 cells. GH3 cells were treated
every 12 h with 1.25 M BB-ClA for 0, 12, 24, or 48 total hours. Following cell lysis, RNA was puriﬁed, reverse transcribed,
and subjected to qPCR analysis using intron-spanning primers speciﬁc to HMGA1 (A), N-MYC (B), or IGF-1 (C). GAPDH was
used as an endogenous reference control. Means were separated with a one-way repeated-measures ANOVA with a post
hoc Dunnett’s t test (n 3). Following the same paradigm, HMGA1 (D), N-MYC (E), and IGF-1 (F) were examined by Western
blotting. pri-let7c-2 (G), pri-miR-23b (H), and pri-miR-29c (I) expression was examined by qPCR after 24 and 48 h of BB-ClA
treatment to conﬁrm that pri-miRNAs were increased when oncogene expression was suppressed. Means were separated
with a one-way repeated-measures ANOVA with a post hoc Dunnett’s t test (n  5). All values provided are means  SEM.
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pri-miRNAs let-7c-2, miR-23b, and miR-29c were signiﬁcantly elevated compared to
DMSO controls (n  5; P  0.05) (Fig. 6G to I). These data suggest that PAD inhibition
promotes increased miRNAs that bind to target sequences within the HMGA1, IGF-1,
and N-MYC mRNAs to decrease their expression.
Antagomirs to miRNAs let-7c-2, 23b, and 29c attenuate oncogene repression in
the presence of PAD inhibition. Our results suggest that PADs may promote tumor
proliferation by repressing miRNAs that target HMGA1, IGF-1, and N-MYC, thus allowing
increased oncogene expression. Yet a direct relationship between let-7c-2, miR-23b,
and miR-29c and oncogene mRNA expression in GH3 cells has not been shown. To
address this, GH3 cells were transiently transfected for 48 h with antagomirs that
speciﬁcally target let-7c-2, miR-23b, and miR-29c and simultaneously treated with
DMSO or 1.25 M BB-ClA every 12 h. qPCR analysis shows that similar to the results in
Fig. 6A to C, HMGA1, IGF-1, and N-MYC mRNAs were signiﬁcantly suppressed with
BB-ClA treatment compared to those in DMSO-treated controls (n  3; P  0.05 and
P  0.01) (Fig. 7). Antagomirs for let-7c-2, miR-23b, and miR-29c all prevented a
decrease in HMGA1, N-MYC, and IGF-1 mRNA expression in the presence of PAD
inhibition by BB-ClA. Our results indicate that these PAD2-regulated miRNAs directly
target the HMGA1, N-MYC, and IGF-1 mRNAs.
PAD inhibition attenuates GH3 proliferation. If histone citrullination indirectly
elevates oncogenic mRNA, then it seems likely that this mechanism will increase
proliferation rates of GH3 cells. To test this, we investigated if PAD inhibition alters GH3
cellular proliferation rates compared to those in vehicle-treated controls. Equal num-
bers of GH3 cells were treated every 12 h with 1.25 M BB-ClA or DMSO for 24, 48, 72,
or 96 total hours. At each time point, cellular proliferation was measured using a
standard 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) prolif-
eration assay. Our results show that PAD inhibition with BB-CLA signiﬁcantly attenuated
cellular proliferation relative to that in vehicle-treated controls at 72 and 96 h (n  3;
P  0.05) (Fig. 8A). To corroborate these results, we also performed cell growth assays
and quantiﬁed GH3 cells at 24, 48, 72, or 96 h following treatment with 1.25 M BB-ClA
or DMSO every 12 h. Similar to the MTT assay, results show that with 72 and 96 h of
BB-ClA treatment there was a signiﬁcant reduction in cell growth compared to that in
DMSO-treated controls (n  5; P  0.05 and P  0.01) (Fig. 8B). Cell viability was
simultaneously measured using trypan blue exclusion, which found no signiﬁcant
difference between vehicle and BB-ClA treatment at 24, 48, or 72 h and a slight
decrease in viability at 96 h (n  6; P  0.01) (Fig. 8C). These data are consistent with
Fig. 4, which shows elevations in miRNAs, and Fig. 6, which demonstrates decreased
oncogene mRNAs, and the data collectively indicate that PAD inhibition ultimately
reduces GH3 proliferation.
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FIG 7 Antagomirs to let7c, miR-23b, and miR-29c attenuate oncogene mRNA expression in the presence of PAD inhibition.
GH3 cells were transiently transfected with vehicle, let7c, miR-23b, and miR-29c antagomirs for 48 h. Immediately following
transfection, cells were treated every 12 h with DMSO or 1.25 M BB-ClA for 48 total hours. RNA was puriﬁed, reverse
transcribed, and subjected to qPCR analysis using intron-spanning primers speciﬁc to HMGA1 (A), N-MYC (B), or IGF-1 (C).
GAPDH was used as an endogenous reference control. Means were separated with a one-tailed paired t test. All values
provided are means  SEM.
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DISCUSSION
Our work deﬁnes a new role for PADs in epigenetic regulation of miRNA gene
expression and shows that PAD2 and -4 and citrullinated histones are elevated in
human prolactinomas and somatoprolactinomas. Mechanistically, PAD-catalyzed citrul-
lination of H3Cit2,8,17 represses the expression of let-7c-2, miR-23b, and miR-29c.
Without these tumor suppressor miRNAs, oncogenic HMGA1, N-MYC, and IGF-1 mRNAs
increase resulting in cellular proliferation. Conversely, when PADs are inhibited or
knocked down, tumor suppressor miRNAs are reexpressed and target oncogene mRNAs
for repression and degradation, thereby suppressing proliferation (Fig. 9).
Compared to PAs, normal human pituitary tissues display low PAD2 and -4 staining.
Our past work shows that PAD expression in female mouse pituitaries varies signiﬁ-
cantly across the estrous cycle and a similar trend in expression may occur in human
pituitaries during the menstrual cycle (2, 21). Low expression in female pituitaries may
simply reﬂect that the tissues were collected on a day of the menstrual cycle associated
with low PAD expression. Low expression in normal human males is supported by
previous studies of rodents which found that PAD expression is sexually dimorphic,
with little expression in male pituitaries (10). Understanding the sexually dimorphic
expression of PADs in pituitaries is the focus of ongoing investigations in our lab.
PAD inhibition results in a signiﬁcant increase in expression of primary and mature
let-7c, miR-23b, and miR-29c in GH3 cells and in pri-miRNAs in mouse pituitary cells
compared to controls. Currently, BB-ClA is the most potent PAD inhibitor, yet it
achieved only an approximately 50% reduction in histone citrullination (41). Despite
this, elevated miRNAs following PAD inhibition are not unprecedented, as Cui et al.
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FIG 8 PAD inhibition attenuates GH3 proliferation. GH3 cells were treated every 12 h with DMSO or 1.25 M BB-ClA for
24, 48, 72, or 96 total hours. (A) To quantify proliferation, the MTT tetrazolium reagent was added to each well. After 2 h,
the resulting formazan solution was collected and the absorbance measured at 490 nm. Means were separated with
one-tailed paired t tests (n  3). (B and C) Cell growth (B) and viability (C) for DMSO and 1.25 M BB-ClA treated GH3 cells
were measured at 24, 48, 72, or 96 total hours using a Countess automated cell counter. Means were separated with
one-tailed paired t tests (n  5). All values provided are means  SEM.
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FIG 9 A working model for PAD catalyzed histone citrullination in lactotrope and somatolactotrope proliferation.
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showed that the same mechanism is associated with the reexpression of miR-16 in
colon cancer cells (42). Our ChIP studies are the ﬁrst to show that histone citrullination
is directly associated with the regulation of miRNA genes. In GH3 cells, the changes in
mature miRNAs are not as robust as with pri-miRNAs, particularly with respect to let-7.
This may occur because the let-7 TaqMan probe detects the mature miRNAs processed
from both let-7c-1 and let-7c-2, while histone citrullination only controls the expression
of the let-7c-2 isoform. Additionally, the fold changes in primary cell pri-miRNAs
following BB-ClA treatment are lower than those from GH3 cells; however, this may be
attributed to the heterogeneous cell population derived from the mouse pituitary
gland.
Gene expression analyses have detected decreased let-7 miRNA in prolactinomas
and somatoprolactinomas (23, 27, 32). let-7 miRNAs target and induce destabilization
and subsequent degradation of oncogene mRNAs, including HMGA isoforms (24, 27,
28). Our ﬁndings suggest that aberrant PAD expression may increase histone citrulli-
nation, which suppresses let-7c expression, resulting in elevated oncoprotein levels.
Although histone citrullination suppresses miR-23b expression in GH3 cells, Bottoni et
al. showed that it is upregulated in human somatoprolactinomas (23). In contrast,
Leone et al. observed signiﬁcant downregulation of miR-23b in human somatotrope
adenomas; however, it is unclear if these adenomas included GH/PRL-secreting so-
matoprolactinomas (33). Our studies are the ﬁrst to show regulation of miR-29c in GH3
cells, although the clinical signiﬁcance of this in PAs is unknown. An important
implication from our work is that PAD-catalyzed histone citrullination is a plausible
mechanism by which let-7c-2, miR-23b, and miR-29c are downregulated in PAs. Evi-
dence of such epigenetic regulation of miRNA gene expression is not unprecedented
(25). For example, DNA hypermethylation decreases let-7 and miR-23b expression and
subsequently contributes to tumorigenesis (43, 44). In contrast, treatment of pituitary
cells with the DNA methyltransferase inhibitor zebularine and the histone deacetylase
inhibitor trichostatin A slows proliferation by inducing the reexpression of oncogene-
targeting miRNAs (45). Our work shows that PAD-catalyzed histone citrullination re-
presses tumor suppressor miRNA expression, which is potentially important in PA
etiology.
PAD inhibition or knockdown facilitates increased miRNA expression, which results
in a decrease in HMGA1, N-MYC, and IGF-1 mRNA. Our siRNA studies suggest that PAD2
is the predominant isoform that regulates pri-miRNA expression. Blocking miRNAs with
antagomirs alleviates the BB-ClA-induced repression of HMGA1, N-MYC, and IGF-1
mRNA expression and demonstrates a direct relationship between the two. Interest-
ingly, these target mRNAs are associated with the G1/S cell cycle transition, and
previous studies found that PAD inhibition or knockdown arrests cells at the same
checkpoint (40, 42, 46–48). HMGA proteins modulate gene expression by altering
chromatin architecture and are highly expressed in embryonic tissues, with minimal
expression in adults (46). Reactivation of HMGA proteins in adult tissues is thought to
promote tumorigenesis by displacing histone deacetylase 1 from the pRB/E2F-1 com-
plex, which allows for the acetylation and activation of the proliferative effects of E2F-1
(67, 68). Furthermore, female transgenic mice overexpressing either HMGA1 or -2
almost exclusively develop GH/PRL-secreting somatoprolactinomas (35, 36). Previous
work has demonstrated that let-7 targets the HMGA 3= UTRs to promote transcript
degradation (32). In agreement with our data, overexpression or upregulation of let-7
in GH3 cells decreases HMGA1 mRNA and attenuates cellular proliferation in a time-
dependent manner (27, 32, 45). Our work suggests that miR-29c may also target
HMGA-1 given that the antagomir to miR-29c prevents HMGA1 repression. IGF-1 is
aberrantly expressed in prolactinomas of both human and diethylstibestrol (DES)-
treated ACI rats, and abrogated IGF-1 signaling is strongly linked to the pathogenesis
of many cancers (37, 38, 51). TargetScan and visual analyses identiﬁed several binding
sites for let-7, miR-23b, and miR-29c within the IGF-1 mRNA sequence, and previous
research showed that let-7 and miR-29c alter IGF-1 mRNA (52, 53). N-MYC is implicated
in many cancers, and studies have characterized binding sites for let-7 and miR-29c
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within N-MYC mRNA (40, 54, 55). It is important to point out that our RNA-seq data
identiﬁed other miRNAs that are increased following PAD inhibition. Thus, we cannot
rule out the possibility that the decrease in HMGA1, N-MYC, and IGF-1 mRNAs in GH3
cells following BB-ClA treatment was exclusively due to let-7c, miR-23b, or miR-29c.
Although our RNA-seq data do not show a change in HMGA1, N-MYC, and IGF-1
expression following 14 h of BB-ClA treatment, we cannot eliminate the possibility that
their genes are also regulated by histone citrullination at 48 h. Nonetheless, our studies
suggest that PAD-mediated repression of tumor suppressor miRNAs promotes the
overexpression of oncogenic proteins, which may contribute to the pathogenesis of
prolactinomas and somatoprolactinomas.
In conclusion, we propose a model in which aberrant PAD expression and the
resulting high levels of citrullinated histones act to suppress the expression of let-7c,
miR-23b, and miR-29c, thereby allowing the reexpression of the HMGA1, N-MYC, and
IGF-1 oncogenes, which drive cellular proliferation. These effects, however, can be
prevented or reversed by knocking down PAD expression or blocking citrullination with
the PAD inhibitor BB-ClA (Fig. 9). Studies to test whether inhibiting PAD activity in vivo
alters oncogene mRNA proﬁles and cellular proliferation of primary lactotrope cells are
under way. Although off-target effects are a legitimate concern, PAD inhibitors may
represent novel therapeutic modalities for treatment of proliferation in the multiple
cancers that overexpress PAD enzymes and contain citrullinated histones.
MATERIALS AND METHODS
Materials. The anti-PAD2 (12110-1-AP), IGF-1 (20215-1-AP), and N-Myc (10159-2-AP) antibodies were
obtained from ProteinTech (Rosemont, IL), and the anti-PAD4 antibody (P4749) was from Sigma-Aldrich
(St. Louis, MO). The anti--actin (Ab8227), anti-histone H3 (Ab1791), anti-H3Cit2,8,17 (Ab5103), and
anti-HMGA1 (Ab129153) antibodies are from Abcam Inc. (Cambridge, MA). The let-7c-2-5p (IH-320289-
05-0002), miR-23b-3p (IH-320310-05-0002), and miR-29c-3p (IH-320322-06-0002) antagomirs as well as
the nontargeting (sense, UUCUCCGAACGUGUCACGU-dTdT; antisense, ACGUGACACGUUCGGAGAA-
dTdT), PAD2 (sense, CCCGUUCUUUGGCCAGCGC-dTdT; antisense, GCGCUGGCCAAAGAACGGG-dTdT),
and PAD4 (sense, GAAGGAUUUCCCUGUCAAA-dTdT; antisense, UUUGACAGGGAAAUCCUUC-dTdT)
siRNAs were purchased from Dharmacon (Lafeyette, CO). The PAD inhibitor BB-ClA was generously
provided by Paul R. Thompson (University of Massachusetts, Worcester, MA) and was synthesized as
previously described (41). Rat PAD4 blocking peptide (MAQGAVIHVAPEEPT) was synthesized by and
purchased from GenScript (Piscataway, NJ).
Cell culture and transient transfection. GH3 cells were obtained from Clay and Colorado State
University and authenticated by treatment with E2 and quantiﬁcation of c-myc and parvalbumin
expression (56). GH3 cells were maintained as previously described (31). For the MTT assay, miRNA target
qPCR, and antagomir studies, complete medium was used since longer exposure to BB-ClA was required.
Complete medium was also necessary for primary culture experiments to allow cell survival. In remaining
experiments, cells were plated and incubated before treatments in phenol red-free, charcoal-stripped
fetal bovine serum (FBS) medium as previously described (56, 57). For PAD siRNA and antagomir
transient-transfection studies, equal numbers of GH3 cells were plated and then transfected the
following morning with 35 nM siRNAs or 30 nM antagomirs using DharmaFECT 1 (GE Healthcare,
Chicago, IL) for 48 h according to manufacturer protocols. GH3 cells transfected with antagomirs were
treated with DMSO or 1.25 M BB-ClA every 12 h for 48 h.
IHC and immunocytochemistry (ICC). A normal human pituitary tissue array slide was obtained
from US Biomax, Inc. (PIT501; Derwood, MD). Pituitary tumor samples and their subtype pathology were
obtained from Institut D’Investigacions Biomediques August Pi i Sunyer Biobanc (Barcelona, Spain).
Samples were deidentiﬁed and thus were exempt from University of Wyoming institutional review board
(IRB) approval (protocol number 20140814BC00496). Immunohistochemistry (IHC) was performed as
previously described (58, 59). Brieﬂy, slides were incubated with anti-PAD2, -PAD4, or -H3Cit2,8,17
antibodies at 1:100 in 1 phosphate-buffered saline (PBS) overnight at 4°C, and negative-control slides
were incubated with an equal mass of nonspeciﬁc rabbit IgG (Vector Laboratories). Images were taken
with a Zeiss Axio Vert.A1 microscope using the 10, 20, and 40 objectives.
For ICC, GH3 cells were grown in MatTek 35-mm glass-bottom dishes (Ashland, MA). After being ﬁxed
and permeabilized, cells were incubated with primary antibodies (anti-PAD2, 1:100, or anti-PAD4, 1:100)
overnight at 4°C. Duplicate dishes were incubated with an equal mass of nonspeciﬁc rabbit IgG as a
negative control. Samples were imaged by a Zeiss LSM 710 confocal microscope under a 40 objective.
Western blotting. Positive controls for the anti-H3Cit2,8,17 antibody were generated by in vitro
citrullination of bulk histones. For PAD2 and PAD4 antibody positive controls, GH3 cells were transiently
transfected with PAD2 or PAD4 expression plasmids for 24 h following the Mirus Bio TransIT-2020
(Madison, WI) transfection protocol. To determine the cross-reactivity of human PAD4 antibody with the
rat PAD4 isoform, the antibody was diluted 1:1,000 in blocking buffer and then equally divided between
two tubes. Rat PAD4 blocking peptide (400 g/ml) was added to one tube and incubated overnight at
4°C with agitation. Samples of GH3 cell lysates and GH3 cells overexpressing human PAD4 were run side
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by side on a 10% SDS-PAGE gel, and the membrane cut in half. Membranes were probed with the
anti-PAD4 antibody or anti-PAD4 antibody preabsorbed with the rat blocking peptide.
For histone citrullination, GH3s were plated in 70-mm culture dishes and treated with 1.25 M BB-ClA
or dimethyl sulfoxide (DMSO) vehicle every 3 h for 14 total hours. Histones were puriﬁed as described by
Shechter et al. (60). GH3 cells were lysed in radioimmunoprecipitation assay (RIPA) buffer and Western
blotting was performed as previously described (49). Protein concentrations were determined by Pierce
660-nm protein assay for equal loading. Samples were then subjected to SDS-PAGE using 10% (PAD
blots) or 15% gels (histone blots). Membranes were incubated overnight at 4°C with primary antibodies:
anti-PAD2 (1:2,000), anti-PAD4 (1:1,000), anti--actin (1:5,000), anti-H3Cit2,8,17 (1:1,000) (0.9 g/l),
anti-HMGA1 (1:10,000), anti-IGF-1 (1:500), anti-N-Myc (1:500), anti-histone H3 (1:5,000). Membranes were
visualized on a Bio-Rad Chemidoc XRS using SuperSignal West Pico and Femto chemiluminescence
substrate (Pierce, Rockford, IL). As loading controls, PAD blots were examined for -actin, while
citrullinated histone blots were probed for total histone H3. Results were quantiﬁed using Bio-Rad Image
Lab software.
Quantitative PCR. RNA was puriﬁed following the Omega Bio-Tek E.Z.N.A. total RNA kit I protocol
(Omega Bio-Tek, Inc., Norcross, GA). One microgram of the puriﬁed RNA was reverse transcribed using
iScript reverse transcription (RT) supermix for RT-qPCR (Bio-Rad, Hercules, CA). cDNA was subjected to
qPCR analysis using intron-spanning rat-speciﬁc primers (pri-let-7c-2, TAGGAGGGACCTCGAGAAGC [for-
ward] and AAGGCCGTCAGTCAGTCTTG [reverse]; pri-miR-23b, CATGTGGATGGGAGTGGTT [forward] and
CAAATCAGCATGCCAGGAA [reverse]; pri-miR-29c, AGGACTGCTTCATTCACATCAG [forward] and ACCAGG
ACTGAGTGCTCCAC [reverse]; HMGA1, GTCAGAAGGAGCCCAGTGAA [forward] and CCCCGGAGTTGTGGT
AACT [reverse]; IGF-1, ACTGACATGCCCAAGACTCA [forward] and TCCTTTGCAGCTTCCTTTTC [reverse];
N-Myc, GTGTCTGTCCCGGCTGTAG [forward] and TCCTCCTCATCGTCTTCATCA [reverse]; PAD2, TGGACCG
ATGTCTACAGTGC [forward] and CACCCTCCGAGTGCTTCA [reverse]; PAD4, GCTGGGAAGGATCAGAGCAC
[forward] and GGGAGTCTTCGTGCTTAGGG [reverse]; glyceraldehyde-3-phosphate dehydrogenase [GAPDH], CA
ACTCCCTCAAGATTGTCAGCAA [forward] and GGCATGGACTGTGGTCATGA [reverse]). For mature miRNA
analyses, cells were treated as described above but miRNAs were puriﬁed per the Omega Bio-Tek E.Z.N.A.
miRNA kit (Omega Bio-Tek, Inc.) protocol. miRNAs were reverse transcribed using the TaqMan microRNA
reverse transcription kit (Thermo Scientiﬁc) and small-RNA-speciﬁc stem-loop primers that were pooled
according to Applied Biosystem’s user bulletin PN 4465407 primer pool protocol. TaqMan probes for
let7c-2-5p (assay identiﬁer [ID] 000379, catalog no. 4427975), miR-23b-3p (0004000, 4427975), miR-
29c-3p (000587, 4427975), and U6 snRNA (001973, 4427975) were purchased from Thermo Fisher. All
qPCR data were analyzed using the threshold cycle (2ΔΔCT) method using GAPDH for pri-miRNAs and
mRNAs and U6 snRNA for mature miRNAs as reference genes (50).
Euthanasia and pituitary collection were performed in accordance with the guidelines outlined in the
report of the AVMA on euthanasia (66). All work in this study was approved by the University of Wyoming
Institutional Animal Care and Use Committee (protocol 20141104BC00129-02). For primary cell experi-
ments, FVB wild-type mice were euthanized and pituitaries (n  7) were explanted and dispersed as
previously described (61). Cells were suspended in complete GH3 medium and the following morning
treated with 1.25 M BB-ClA or DMSO every 3 h for 14 total hours. RNA was puriﬁed, reverse transcribed,
and analyzed by qPCR using mouse-speciﬁc primers (Pri-let-7c-2, TTCCTCTAGGAGGGACCTCAA [forward]
and CGTCAGTCAGTCTTGGCGTA [reverse]; pri-miR-23b, TTGTCTCCCAGTCCCCTATG [forward] and GTGC
AGCCTGCTGTCCTT [reverse]; pri-miR-29c, CAGACTGTCACCTGCCTTGA [forward] and GGAGAAATCGGTC
AGCCTGT [reverse]; GAPDH, GGGTTCCTATAAATACGGACTGC [forward] and CCATTTTGTCTACGGGACGA
[reverse]).
Illumina RNA sequencing. Three independent sets of GH3 cell RNA were generated as described
above. RNA samples were sent to the National Center for Genomic Resources (NCGR; Santa Fe, NM). RNA
libraries were prepared using the Illumina TruSeq library kit. A polyadenylation step during library
preparation ensured retention of mRNA in the samples. Libraries were sequenced on HiSeq 2000 to
generate 1  50 reads (single end reads). Adapters and primer sequences were removed during
postprocessing.
Postprocessed high-quality reads for all samples were aligned to the Rattus norvegicus genome,
downloaded from the GenBank repository (GCA_000001895.4). An associated annotation ﬁle in GFF
format was used to obtain genic information to generate read counts. Alignments were generated using
GSNAP (version released on 29 December 2014) using the following parameters: indel penalty  2,
maximum mismatches  0.06, and everything else at default (62). Alpheus, an in-house pipeline, was
used to generate reads (63). Gene expression for each sample was calculated as a measure of the total
number of reads aligning uniquely to the reference, binned by genic coordinates (information obtained
from the annotation ﬁle). Differential gene expression analysis was performed using the Bioconductor
package DESeq2 (64). Raw read counts obtained were normalized to account for differences in sequenc-
ing depth and composition using methods implemented within DESeq2. Differential expression of
pairwise comparisons was assessed using the negative binomial test, and comparisons that were
signiﬁcantly differentially expressed were deﬁned as candidates that had an adjusted P value of 0.05
(65).
ChIP. GH3 cells were plated in 15-cm plates and treated as described above. Chromatin immuno-
precipitation (ChIP) was then performed following the SimpleChip Plus enzymatic chromatin IP kit
protocol (Cell Signaling Technologies, Danvers, MA), optimized for GH3 cells. The ChIP primer sequences
were identical to the primer sets used for RT-qPCR. All values are expressed as percent input.
Cell proliferation, growth, and viability assays. GH3 cells were treated every 12 h with either
DMSO or 1.25 M BB-ClA. At 24, 48, 72, and 96 h, medium was removed from the corresponding wells
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and replaced with 500 l of complete medium and 20 l of CellTiter 96 AQueous One solution reagent
from the CellTiter 96 AQueous One cell proliferation assay (Promega Corporation, Madison, WI). After
incubation for 2 h at 37°C, the absorbances of 100 l were measured at 490 nm. For cell growth and
viability, equal numbers of GH3 cells were seeded into 6-well plates and then treated with DMSO or 1.25
M BB-ClA every 12 h. At 24, 48, 72, and 96 h, cells were counted and examined for viability using trypan
blue following standard protocols for an Invitrogen Countess automated cell counter.
Statistics. All statistical analyses were performed with GraphPad Prism 6.0. Results were analyzed for
signiﬁcance using two-tailed t tests unless otherwise noted. All experiments were repeated at least three
independent times. Values are given as means  standard errors of the means (SEM).
Accession number(s). RNA sequencing data were deposited in the NCBI database with BioProject ID
PRJNA422458.
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